Compare Airbnb, Inc. (ABNB) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Airbnb, Inc. vs Moderna, Inc. — how do they compare? Airbnb, Inc. trades at $180.6 (market cap $110.76B), while Moderna, Inc. trades at $63.87 (market cap $24.18B). The key difference: Airbnb, Inc. is far larger — about 4.6× Moderna, Inc.'s market cap, and Airbnb, Inc. is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.
| ABNB | MRNA | |
|---|---|---|
Market Cap | $110.76B | $24.18B |
Sector | Consumer Cyclical | Health |
52-Week High | $184.98 | $81.80 |
52-Week Low | $111.54 | $22.36 |
Enterprise Value | $101.19B | $20.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABNB trades at $180.06, down 2.51% today but remains near recent highs following strong Q2 2026 earnings that beat expectations. The stock shows bullish technical momentum with moving averages supporting upward trends, though oscillators indicate potential overbought conditions. Fundamentally, Airbnb demonstrates robust revenue growth with $12.24B in 2025 revenue and impressive 82.9% gross margins, though valuation multiples remain elevated with a P/E of 42.23. Recent news highlights the company's strategic pivot toward AI integration and expansion into hotel listings and travel services.
The outlook remains positive with analyst consensus leaning toward Buy (46.7% of ratings) and a $173.26 price target, though current price exceeds this consensus. Key opportunities include AI-driven efficiency gains and travel demand recovery, while risks involve premium valuation sensitivity and competitive pressures in the evolving travel marketplace. Institutional sentiment appears cautiously optimistic given recent earnings momentum.
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Airbnb, Inc.
Airbnb, Inc. operates an online marketplace for travel information and booking services. The Company offers lodging, home stay, and tourism services via websites and mobile applications. Airbnb serves clients worldwide.
Read more on ABNB →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
